A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …

Chronic myelogenous leukemia (CML) presents a unique opportunity to develop therapeutic
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …

BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …

Peptides from the e14a2 BCR-ABL junction will elicit T-cell responses in vitro. Here, 19
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …

Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …

In this pilot study, we investigated the ability of autologous dendritic cells (DCs) pulsed ex
vivo with leukemia-specific peptide to stimulate host antitumor immunity when administrated …

Chronic myelogenous leukemia (CML) is a clonal disorder characterized by proliferation of
cells that possess the bcr-abl fusion gene resulting in the production of one of two possible …

Chronic myelogenous leukemia (CML) is characterized by at (9; 22) translocation, which
results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for …

The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen
in chronic lymphocytic leukemia (CLL). CD8+ T cells primed with the RHAMM-derived …

Chronic myelogenous leukemia (CML) cells are characterized by at (9; 22) translocation,
which can encode one of two chimeric P210 bcr-abl fusion proteins, comprising products of …